CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← X4 Pharmaceuticals, Inc (XFOR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

X4 Pharmaceuticals, Inc (XFOR)

Biological Products, (No Diagnostic Substances) · market cap $312M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-09-15 (est.)
Phase 3
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
X4 Pharmaceuticals (XFOR) is a small-cap biotech (market cap ~$322M, 143 employees, price ~$3.25) with mavorixafor as its lead asset, listed in our data as Phase 3 for WHIM Syndrome. Our data also lists X4P-001 (Phase 2, WHIM Syndrome) and axitinib (Phase 2, clear cell renal cell carcinoma). The company reports $195.1M cash, 28.2 months of runway and net cash of ~$120M. The next major event on our calendar is an estimated Phase 3 mavorixafor readout on 2027-09-15.
The catalyst path
  • 2027-09-15 (est.)Phase 3 · Mavorixaforimp 9/10
Pipeline
AssetPhaseIndication
X4P-001Phase 2WHIM Syndrome
MavorixaforPhase 3WHIM Syndrome
axitinibPhase 2Clear Cell Renal Cell Carcinoma
Price & technical context
3-month
-27.4%
6-month
-20.8%
12-month
-19.4%
52-wk range
$2.45–$4.67
vs 50-day MA
-1.0%
vs 200-day MA
-17.4%
Realized vol
70.8%
Max drawdown
-94.1%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for XFOR (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.